MRES: Dr. Esmarilda Dankaert Appointed Chief Innovation Officer (CINO) at M2Bio Sciences
M2Bio Sciences (OTC PINK:MRES) has appointed Dr. Esmarilda Dankaert as Chief Innovation Officer (CINO). Dr. Dankaert, a Counselling Psychologist with a doctorate from the University of Johannesburg, will lead technological advancements across M2Bio's divisions, focusing on integrating AI for mental health interventions. She brings extensive experience in psychology, psychometry, quality assurance, and AI ethics. Between January and February 2025, she will visit M2Bio's Dubai offices, delivering keynote speeches and engaging with stakeholders across the Middle East. Her role will focus on developing AI-driven technologies for mental health solutions and advancing the company's research capabilities in biotechnology and nutraceuticals.
M2Bio Sciences (OTC PINK:MRES) ha nominato la Dott.ssa Esmarilda Dankaert come Chief Innovation Officer (CINO). La Dott.ssa Dankaert, psicologa clinica con un dottorato presso l'Università di Johannesburg, guiderà i progressi tecnologici in tutte le divisioni di M2Bio, concentrandosi sull'integrazione dell'IA per interventi nella salute mentale. Porta con sé una vasta esperienza in psicologia, psicometria, assicurazione qualità ed etica dell'IA. Tra gennaio e febbraio 2025, visiterà gli uffici di M2Bio a Dubai, tenendo discorsi principali e interagendo con gli stakeholder in tutto il Medio Oriente. Il suo ruolo si concentrerà sullo sviluppo di tecnologie guidate dall'IA per soluzioni nella salute mentale e sul potenziamento delle capacità di ricerca dell'azienda in biotecnologia e nutraceutici.
M2Bio Sciences (OTC PINK:MRES) ha nombrado a la Dra. Esmarilda Dankaert como Directora de Innovación (CINO). La Dra. Dankaert, psicóloga clínica con un doctorado de la Universidad de Johannesburgo, liderará los avances tecnológicos en las divisiones de M2Bio, enfocándose en la integración de la IA para intervenciones en salud mental. Aporta una amplia experiencia en psicología, psicometría, aseguramiento de calidad y ética de la IA. Entre enero y febrero de 2025, visitará las oficinas de M2Bio en Dubái, ofreciendo discursos magistrales y participando con las partes interesadas en todo el Medio Oriente. Su papel se centrará en desarrollar tecnologías impulsadas por IA para soluciones en salud mental y en avanzar las capacidades de investigación de la empresa en biotecnología y nutracéuticos.
M2Bio Sciences (OTC PINK:MRES)는 Dr. Esmarilda Dankaert를 최고 혁신 책임자(CINO)로 임명했습니다. Dankaert 박사는 요하네스버그 대학교에서 박사 학위를 가진 상담 심리학자로, M2Bio의 각 부서에서 기술 발전을 이끌며 정신 건강 개입을 위한 AI 통합에 집중할 것입니다. 그녀는 심리학, 심리 측정, 품질 보증 및 AI 윤리에 대한 폭넓은 경험을 보유하고 있습니다. 2025년 1월과 2월 사이에 그녀는 M2Bio의 두바이 사무소를 방문하며, 기조 연설을 하고 중동 전역의 이해관계자들과 소통할 예정입니다. 그녀의 역할은 정신 건강 솔루션을 위한 AI 기반 기술 개발과 생명공학 및 뉴트라슈티컬 분야에서 회사의 연구 능력 향상에 초점을 맞출 것입니다.
M2Bio Sciences (OTC PINK:MRES) a nommé Dr. Esmarilda Dankaert au poste de Directrice de l'Innovation (CINO). Dr. Dankaert, psychologue conseil titulaire d'un doctorat de l'Université de Johannesburg, sera chargée de diriger les avancées technologiques dans les différentes divisions de M2Bio, en se concentrant sur l'intégration de l'IA pour des interventions en santé mentale. Elle possède une vaste expérience en psychologie, psychométrie, assurance qualité et éthique de l'IA. Entre janvier et février 2025, elle visitera les bureaux de M2Bio à Dubaï, prononçant des discours magistraux et interagissant avec les parties prenantes dans tout le Moyen-Orient. Son rôle sera axé sur le développement de technologies pilotées par IA pour des solutions en santé mentale et sur le renforcement des capacités de recherche de l'entreprise en biotechnologie et nutraceutiques.
M2Bio Sciences (OTC PINK:MRES) hat Dr. Esmarilda Dankaert zur Chief Innovation Officer (CINO) ernannt. Dr. Dankaert, eine Psychologin mit einem Doktortitel von der Universität Johannesburg, wird technologische Fortschritte in den verschiedenen Abteilungen von M2Bio leiten und sich auf die Integration von KI für Interventionen im Bereich der psychischen Gesundheit konzentrieren. Sie bringt umfangreiche Erfahrungen in Psychologie, Psychometrie, Qualitätsmanagement und KI-Ethische mit. Zwischen Januar und Februar 2025 wird sie die Büros von M2Bio in Dubai besuchen, Hauptvorträge halten und mit Stakeholdern im gesamten Nahen Osten zusammenarbeiten. Ihre Rolle wird sich auf die Entwicklung von KI-gesteuerten Technologien für Lösungen im Bereich der psychischen Gesundheit und die Weiterentwicklung der Forschungskapazitäten des Unternehmens in Biotechnologie und Nutraceuticals konzentrieren.
- Strategic appointment of experienced professional with multidisciplinary background
- Expansion of technological capabilities through AI integration
- Planned business development activities in Middle East market
- None.
DUBAI, UAE / ACCESSWIRE / November 25, 2024 / The Institute of Biomedical Research Corp. (OTC PINK:MRES), operating as M2Bio Sciences, is a pioneering biotechnology company dedicated to advancing health and wellness through innovative science-driven solutions. Specialising in researching, developing, and commercialising cutting-edge products in nutrition, health, and sustainability. The company is also committed to groundbreaking research in mental health, gut and oral health, longevity, and comprehensive healthcare solutions. By harnessing advanced technologies and upholding ethical practices, M2Bio Sciences is redefining the future of physical and mental well-being. Aligned with this mission, M2Bio Sciences is pleased to announce the following update:
M2Bio Sciences is excited to announce the appointment of Dr. Esmarilda Dankaert as Chief Innovation Officer (CINO).
Dr. Dankaert will spearhead technological advancements across M2bio Sciences and its M2Biome, M2Sentient, M2BioKids, and M2MMA divisions, strategically focusing on integrating artificial intelligence (AI) to drive innovation and excellence throughout the organisation. Her extensive experience in the fields of psychology, psychometry, quality assurance, and AI ethics will be instrumental in developing human-centered AI applications that enhance mental health interventions and promote ethical standards in technology deployment. Dr. Dankaert's leadership and academic background will advance M2Bio's research capabilities, leading to more effective and ethically sound solutions in mental health care globally.
With a career spanning multiple industries, Dr. Dankaert began her journey as a multimedia and web developer before transitioning to quality assurance. At 18, she became Europe's youngest qualified Quality Auditor Representative. Her subsequent roles in the corporate, academic, clinical, and private sectors have equipped her with a multidisciplinary perspective, providing her with a unique set of skills that sets her apart and equips her to champion human-centered solutions that integrate technology and psychology seamlessly.
Dr. Dankaert is a practicing Counselling Psychologist with a Doctorate in Psychology from the University of Johannesburg. She has a thriving practice in Cape Town, South Africa, and also consults with companies on psychological interventions and advisory services. As a qualified psychometrist, she specialises in the development and application of psychological assessment instruments. Her career has been defined by a passion for empowering individuals through self-knowledge and leveraging technological advancements to unlock human potential. Additionally, Dr. Dankaert has been an expert witness in psycho-legal cases, providing critical psychological insights to the judicial system. Her appointment at M2Bio Sciences marks a pivotal step in the company's mission to revolutionise healthcare and mental well-being through cutting-edge innovation.
"By taking on this new role, I will be able to do more of what I am deeply passionate about, which is helping humans flourish using innovative AI-driven technologies," says Dr. Dankaert. "I see the company at a pivotal, transformative point, where we can leverage technological advancements to reshape how we conceptualise, diagnose, and treat mental health. As leaders in biotechnology and nutraceuticals, M2Bio Sciences is also ideally placed to combine its innovative healthcare solutions for gut and oral microbiome in addressing society's current mental and physical health challenges."
As CINO at M2Bio Sciences, Dr. Dankaert will lead transformative initiatives to develop positive technologies and solutions that enhance mental health. Her work includes leveraging AI to create sentient agents that foster self-awareness, emotional intelligence, and meaningful human connections. Guided by her belief that mental health extends beyond the absence of mental illness, she advocates for a holistic approach that integrates physical and mental health, personal development, purpose-driven work, and the ethical application of AI technologies.
Between January and February 2025, Dr. Dankaert will visit M2Bio Sciences' offices in the Dubai Science Park, United Arab Emirates. She will deliver numerous keynote speeches at major corporations, hospitals, and educational institutions across the UAE and the broader Middle East during this period. Additionally, she will engage with key stakeholders and potential investors to discuss innovative developments in mental health and biotechnology. Dr. Dankaert will also focus on identifying and recruiting top talent to enhance the M2Bio team in Dubai and surrounding regions.
"Dr. Dankaert is a trailblazer at the intersection of psychology and technology, redefining what is possible in the mental health field and positive technologies. Her visionary approach to revolutionising mental health aligns perfectly with our mission to deliver innovative, human-centered healthcare solutions," said Jeff Robinson, CEO of M2Bio Sciences. "The current mental health system remains entrenched in methodologies from the 1970s and 1980s, which are often outdated and ineffective in addressing today's challenges. Dr. Dankaert's expertise and innovative mindset are exactly what we need to disrupt the status quo and implement more effective, modern approaches to mental health care."
M2Bio Sciences is thrilled to embark on this transformative new chapter, confident its strategic initiatives will unlock unparalleled growth opportunities. It is deeply committed to overdelivering exceptional value to its customers, partners, and shareholders. With an invigorated focus on innovation and excellence, we are poised to redefine industry standards and achieve unprecedented success. Our unwavering dedication to pushing boundaries ensures all stakeholders a prosperous and bright future.
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp., trading as M2Bio Sciences, is a bioceutical company that uses groundbreaking technologies to develop innovative healthcare solutions. M2Bio's mission is to revolutionalise mental health and human flourishing by deploying best-practice science and medicine, clinical research, and emerging technologies.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES." Publicly traded Company (OTC Pink: MRES)
Contact:
Jeff Robinson, Chairman and CEO
www.m2bio.co
jeff@m2bio.co
+27 72 333 2148
Dr Esmarilda Dankaert, CINO
www.m2bio.co
DrE@m2bio.co
+27 72 089 3867
Forward-Looking Statement:
This release contains forward-looking statements within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief, or current expectations of Real American Capital Corp., its directors, or its officers concerning, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy.
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
TikTok
Contact Information
Jeff Robinson
Chairman and CEO: M2Bio Sciences
jeff@m2bio.co
+27723332148
Dr Esmarilda Dankaert
Chief Innovation Officer
dre@m2bio.co
+270893867
Related Images
Chief Innovation Officer (CINO) of M2Bio Sciences
M2Bio Sciences Corporation
SOURCE: Institute of BioMedical Research Corp.
View the original press release on accesswire.com
FAQ
Who is the new Chief Innovation Officer at M2Bio Sciences (MRES)?
What will be Dr. Dankaert's main responsibilities at M2Bio Sciences (MRES)?
When will Dr. Dankaert visit M2Bio Sciences' Dubai offices?
